Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2022-03-25 | 2022-04-11 | 157329 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2022-04-08 | 2022-04-22 | 158370 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2024-01-12 | 2024-02-09 | 215979 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2024-06-13 | 2024-07-05 | 230492 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2024-11-15 | 2025-02-14 | 243190 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2019-02-13 | 2019-03-07 | 75629 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-04-18 | 2019-05-13 | 82019 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-06-28 | 2017-10-03 | 14223 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-06-28 | 2017-11-03 | 14227 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-08-08 | 2017-11-07 | 18560 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-08-29 | 2017-10-30 | 20623 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-08-29 | 2017-11-03 | 20626 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2021-04-30 | 2021-05-25 | 138355 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-11-07 | 2018-03-20 | 28440 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-11-28 | 2018-02-27 | 30960 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-11-28 | 2018-03-13 | 31031 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-11-28 | 2018-03-20 | 31034 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2022-12-16 | 2023-01-06 | 178763 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-03-23 | 2023-04-27 | 187730 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2023-04-27 | 2023-05-06 | 190865 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |